Back to results
US 12,747,290 B2Granted
IL-33 binding antibodies
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsMartin Orecchia, Matthew Edwards, Andrew Beaton, Laura Hook
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of interleukin 33 (IL-33) mediated diseases, including lung diseases. In particular, the present disclosure relates to IL-33 binding proteins, including anti-IL-33 antibodies, and their uses in the treatment of IL-33 mediated diseases.
Claims22
An IL-33 binding protein comprising:
- CDRH1 of SEQ ID NO:1, CDRH2 of SEQ ID NO:4, CDRH3 of SEQ ID NO:7, CDRL1 of SEQ ID NO:10, CDRL2 of SEQ ID NO:
- 14, and CDRL3 of SEQ ID NO:
- 18,
- wherein the IL-33 binding protein is an antibody or an antigen binding fragment thereof.
1 more element
Dependencies are inferred from the claim text.